Background and Aim: Hepatocellular carcinoma (HCC) is the third most common reason for cancer-related death worldwide. Many countries either lack appropriate clinical practice guidelines for the ...
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.
Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.
Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Mortality trends and racial disparities in hepatocellular carcinoma associated with metabolic syndrome in the United States and Texas: A 21-year analysis (1999-2020) using CDC WONDER database. This is ...
"To our knowledge, our study represents the first randomized, global study to report data for an anti-TIGIT monoclonal antibody in hepatocellular carcinoma," Finn and colleagues wrote in Lancet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback